Document is current
Any future updates will be listed below
-
Authors
Senkevich, Konstantin https://orcid.org/0000-0003-3407-5716
Liu, Lang https://orcid.org/0000-0002-0348-2258
Alvarado, Chelsea X.
Leonard, Hampton L.
Nalls, Mike A. https://orcid.org/0000-0003-0319-4325
,
Gan-Or, Ziv https://orcid.org/0000-0003-0332-234X
- License Information
-
More Information
Article History
Received: 3 November 2023
Accepted: 26 June 2024
First Online: 5 August 2024
Competing interests
: Z.G.O. received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanquabio Guidepoint, Lighthouse and Deerfield. C.X.A., M.A.N., and H.L.L.’s participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Character Bio Inc. and as an advisor to Neuron23 Inc. The remaining authors declare no competing interests.
